Prostate cancer is a very common cancer, with more than 3 million cases reported each year. Some types of prostate cancer advance slowly, others are much more aggressive.
That is just one of many reasons it is important to identify and treat prostate cancer in its early stages. A new partnership between McLaren Greater Lansing and Michigan State University (MSU) is making it possible.
The partnership will offer new technology, Prostate MR Fusion, that can find more relevant cancers and better identify prostate cancer in patients. MR Fusion is a significant advancement in the ability to diagnose and treat prostate cancer.
“Prostate MR Fusion is an imaging modality which utilizes advanced MRI technology to help identify an area in the prostate where patients may have cancers,” said Dr. Raheel John, a radiologist at the MSU Department of Radiology.
The MR Fusion technology operates in two steps. First, the patient will visit an MSU radiology location and have an MRI of the prostate completed. Next, the patient will be scheduled for an outpatient procedure with his urologist in which the MR Fusion technology will be used to fuse a real-time ultrasound image with the previously performed MRI of the prostate. This allows the physician to locate specific lesions that are troubling. The physician will then take biopsy tissue from the pinpointed lesion.
“The MR Fusion technology should be offered to patients who have undergone previous prostate biopsies that failed to show prostate cancer, but their PSA (prostate-specific antigen ) is still rising, and doctors suspect a cancer might be present,” said Dr, Rafid Yousif of the Lansing Institute of Urology. “The goal of this new technology is to detect aggressive prostate cancers accurately.”
The news should be a relief for men diagnosed with small, slow-growing tumors of the prostate, leading to a reduction to the number of biopsies they need along with a reduced morbidity rate.